Last reviewed · How we verify
Glucose solution
Glucose solution provides exogenous glucose to raise blood glucose levels in hypoglycemic or nutritionally deficient states.
Glucose solution provides exogenous glucose to raise blood glucose levels in hypoglycemic or nutritionally deficient states. Used for Acute hypoglycemia, Nutritional support in patients unable to consume food orally, Perioperative glucose supplementation.
At a glance
| Generic name | Glucose solution |
|---|---|
| Also known as | Dextrose, Glucose 20%, Dextrose Gel, Glucote, glucose 5% |
| Sponsor | University of Sao Paulo |
| Drug class | Carbohydrate supplement / Nutritional agent |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Nutrition / Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
Glucose solution is a simple carbohydrate formulation that delivers glucose directly into the bloodstream or gastrointestinal tract, rapidly increasing blood glucose concentration. It is used to treat acute hypoglycemia, provide nutritional support, and maintain blood glucose homeostasis in patients unable to consume food orally or requiring immediate glycemic correction.
Approved indications
- Acute hypoglycemia
- Nutritional support in patients unable to consume food orally
- Perioperative glucose supplementation
Common side effects
- Hyperglycemia (if overdosed)
- Phlebitis (if administered intravenously)
- Gastrointestinal upset (if administered orally)
Key clinical trials
- Early Methylene Blue in the Microhemodynamics of Septic Patients (PHASE2, PHASE3)
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (PHASE1, PHASE2)
- SODium BICarbonate for Metabolic Acidosis in the ICU (PHASE3)
- A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) (PHASE3)
- Effectiveness of Thoracolumbar Fascia Mobilization and Ultrasound-Guided 5% Dextrose Injection in Chronic Low Back Pain (NA)
- Dexmedetomidine for Invasive Ventilation In the NEOnate (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |